Bio-Rad Laboratories (Bio-Rad Laboratories) ROCE % : 15.25% (As of Dec. 2023)

View and export this data going back to 1980. Start your Free Trial

What is Bio-Rad Laboratories ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bio-Rad Laboratories's annualized ROCE % for the quarter that ended in Dec. 2023 was 15.25%.

Bio-Rad Laboratories ROCE % Historical Data

The historical data trend for Bio-Rad Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories ROCE % Chart

Bio-Rad Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

37.26

50.81

37.00

-31.05

-6.48

Bio-Rad Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															36.13	2.99	-48.64	5.26	15.25

Bio-Rad Laboratories ROCE % Calculation

Bio-Rad Laboratories's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-800.665	/	( ( (13501.666 - 568.708)	+	(12299.07 - 522.799) )	/ 2 )
	=	-800.665	/	( (12932.958	+	11776.271)	/ 2 )
	=	-800.665	/	12354.6145
	=	-6.48 %

Bio-Rad Laboratories's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	1763.012	/	( ( (11895.943 - 558.176)	+	(12299.07 - 522.799) )	/ 2 )
	=	1763.012	/	( ( 11337.767	+	11776.271 )	/ 2 )
	=	1763.012	/	11557.019
	=	15.25 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Bio-Rad Laboratories (NYSE:BIO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bio-Rad Laboratories ROCE % Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BIO.B:USA BUW:Germany BUWA:Germany

Address

1000 Alfred Nobel Drive, Hercules, CA, USA, 94547

Website

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Executives

Tania Devilliers	officer: INT PRIN ACCTG OFC	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Sedat Evran	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Corey Colleen	officer: EVP, Global Human Resources	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Diane Dahowski	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Schwartz Allison	director	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Simon May	officer: EVP, President, LSG	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew J. Last	officer: EVP, Chief Operating Officer	3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Ajit Ramalingam	officer: SVP, Chief Accounting Officer	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Ilan Daskal	officer: EVP, Chief Financial Officer	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Timothy S Ernst	officer: EVP, General Counsel & Sec	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Dara Wright	officer: Executive Vice President	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Michael Crowley	officer: EVP, GBL Commercial Operations	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Steven D Schwartz	10 percent owner	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice N Schwartz	director, 10 percent owner
Norman D Schwartz	director, 10 percent owner, officer: Chairman, President, and CEO	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547